Alloy Thera and Sanofi join forces on CNS drug research

Privately-held US biotech Alloy Therapeutics has announced a target specific collaboration and license agreement for the use of its novel and proprietary anticlastic antisense platform with French pharma major Sanofi (Euronext: SAN) for a central nervous system (CNS) target.

In return, Sanofi will provide Alloy with upfront license fees and near-term preclinical milestone payments up to $27.5 million.  Alloy will also be eligible to receive discovery, development, and commercial milestone payments of over $400 million, as well as tiered royalties on sales of any products resulting from the collaboration.

According to Alloy, this collaboration underscores a shared commitment to advancing innovative therapeutics in the CNS space.